<SEC-DOCUMENT>0001062822-20-000063.txt : 20201029
<SEC-HEADER>0001062822-20-000063.hdr.sgml : 20201029
<ACCEPTANCE-DATETIME>20201029070222
ACCESSION NUMBER:		0001062822-20-000063
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201029
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201029
DATE AS OF CHANGE:		20201029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		201270441

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20201029.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:c8dd698f-3175-4c15-b175-8de9529d1e6f,g:e7b78c0d-300e-459f-a2da-2d0531ddecba,d:ad3b16d241754c53b3528473d4eff8a9--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20201029</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV80L2ZyYWc6MmIyOWUyZjZkYTJkNGI0M2FhYTNkNjU3YjQ4ZjViYmYvdGFibGU6Y2QyN2Q3MzIxY2RlNGNmOTllMjcwMDhjZTQ1ZjRiM2IvdGFibGVyYW5nZTpjZDI3ZDczMjFjZGU0Y2Y5OWUyNzAwOGNlNDVmNGIzYl8wLTEtMS0xLTA_2708a7ff-a57e-4151-b715-c6384dfd4077">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV80L2ZyYWc6MmIyOWUyZjZkYTJkNGI0M2FhYTNkNjU3YjQ4ZjViYmYvdGFibGU6Y2QyN2Q3MzIxY2RlNGNmOTllMjcwMDhjZTQ1ZjRiM2IvdGFibGVyYW5nZTpjZDI3ZDczMjFjZGU0Y2Y5OWUyNzAwOGNlNDVmNGIzYl8xLTEtMS0xLTA_d51d5f33-c02e-45ba-ae1d-f10680e77da8">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20201029.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-29</xbrli:startDate><xbrli:endDate>2020-10-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iad3b16d241754c53b3528473d4eff8a9_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg3_282c8636-84b7-449f-88fb-0f1fd2278c6c">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8yNjY_854c95c3-cffb-438c-aabf-d5478d978c9a">October 29, 2020</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjgw_49e0a411-6141-492b-894c-b6b777c801f0">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6ZGNkMTlkMzg1ZjNmNDg2YzhiNDhmYWU0OGZhNjg5OTQvdGFibGVyYW5nZTpkY2QxOWQzODVmM2Y0ODZjOGI0OGZhZTQ4ZmE2ODk5NF8wLTAtMS0xLTA_a3102990-8f12-46a0-a825-135a2fffed25">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6ZGNkMTlkMzg1ZjNmNDg2YzhiNDhmYWU0OGZhNjg5OTQvdGFibGVyYW5nZTpkY2QxOWQzODVmM2Y0ODZjOGI0OGZhZTQ4ZmE2ODk5NF8wLTEtMS0xLTA_79e5b1d6-1991-41ba-b0f2-2536fca97427">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6ZGNkMTlkMzg1ZjNmNDg2YzhiNDhmYWU0OGZhNjg5OTQvdGFibGVyYW5nZTpkY2QxOWQzODVmM2Y0ODZjOGI0OGZhZTQ4ZmE2ODk5NF8wLTItMS0xLTA_4dbf7b62-0d7f-414d-a0d4-0e4537cab5a7">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg0_51064a4e-e70c-4ecd-8668-5f4a9fa0e867">8800 Technology Forest Place</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjgx_c4e3c6d6-2f3e-403d-9e05-e40c4674e89d">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjkx_5cded6e1-9911-4b2d-811a-2a57f1f6d6a1">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV80MDk_ab8271da-c4c8-426a-b5c4-9a334baf00f8">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV80Njg_45de67f8-5aba-42bb-9e97-eae849f02918">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg4_29e2cc8f-c70e-4aed-877f-fe50fa9a1b66">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6YTZmZDQ0YjE1Nzk3NGQxMzliOTM4NTEyMjNmNGZhYzEvdGFibGVyYW5nZTphNmZkNDRiMTU3OTc0ZDEzOWI5Mzg1MTIyM2Y0ZmFjMV8xLTAtMS0xLTA_6a4c2205-6953-4ed2-ad55-d18e3528e73c">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6YTZmZDQ0YjE1Nzk3NGQxMzliOTM4NTEyMjNmNGZhYzEvdGFibGVyYW5nZTphNmZkNDRiMTU3OTc0ZDEzOWI5Mzg1MTIyM2Y0ZmFjMV8xLTEtMS0xLTA_f5734488-c314-402e-bc94-cb8d3e0cc40e">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6YTZmZDQ0YjE1Nzk3NGQxMzliOTM4NTEyMjNmNGZhYzEvdGFibGVyYW5nZTphNmZkNDRiMTU3OTc0ZDEzOWI5Mzg1MTIyM2Y0ZmFjMV8xLTItMS0xLTA_643af199-3290-4fa4-a368-529645a075a7">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjky_e2dd2f38-a87e-410c-a073-2833c565373f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjk0_542b535e-838d-4d53-8aff-045af3fec4df">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg5_6674df88-fa04-4c88-b95e-8b804697d99a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg2_8e44b3e5-e891-4a17-bc37-e380216fc17a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjgz_157a371a-0297-43b2-b30c-49666c89d2db">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iad3b16d241754c53b3528473d4eff8a9_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operation and Financial Condition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 29, 2020, we issu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ed a press release to report our financial results for the quarter ended September 30, 2020.  A copy of the press release is attached to this current report on Form&#160;8-K as Exhibit&#160;99.1.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="iad3b16d241754c53b3528473d4eff8a9_10"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:13.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearningsq3.htm">Press Release of Lexicon Pharmaceuticals, Inc dated </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearningsq3.htm">October 29</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearningsq3.htm">, 2020</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iad3b16d241754c53b3528473d4eff8a9_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:52.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   October 29, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iad3b16d241754c53b3528473d4eff8a9_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearningsq3.htm">Press Release of Lexicon Pharmaceuticals, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearningsq3.htm">October 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearningsq3.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearningsq3.htm">, 2020</a></span></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>lxrx-20201029.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c8dd698f-3175-4c15-b175-8de9529d1e6f,g:e7b78c0d-300e-459f-a2da-2d0531ddecba-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20201029" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20201029">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201029_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201029_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201029_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201029_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lexpharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>lxrx-20201029_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c8dd698f-3175-4c15-b175-8de9529d1e6f,g:e7b78c0d-300e-459f-a2da-2d0531ddecba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20201029.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lxrx-20201029_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c8dd698f-3175-4c15-b175-8de9529d1e6f,g:e7b78c0d-300e-459f-a2da-2d0531ddecba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20201029.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended" id="i1f37d8e01f064a7b90d1665fbed66996_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lxrx-20201029_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c8dd698f-3175-4c15-b175-8de9529d1e6f,g:e7b78c0d-300e-459f-a2da-2d0531ddecba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_6c537800-b6f8-44de-bfe4-ab660e8932c7_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_378d1355-135a-49c4-97af-6b09686bc10e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2aebcbd1-4ea9-429e-9003-c2441d9b6cfd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ea8b552a-eb3e-4c80-8980-e7c661fba7b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_f52ae585-1566-434f-82c8-a8493686a2fe_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2534261c-f918-44d9-a1ab-b04e93caa95d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_38a8fbb7-02e6-4208-9a6a-2d47e50976e0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d3762e3c-825c-405a-8b94-9f496dcbd13f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_62a97be0-2db9-4b5e-b9a1-154993608d5d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_532d91bf-01cf-45e4-81c8-ed606d83ef69_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dd64c87b-dc7f-41a9-8aa4-8fbcace09f41_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_61e45a2a-c056-4b89-b61b-f70b3bf8da9d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6aa18291-c39e-4097-8b26-360f5cf1279c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3b17e05e-485a-428b-b45e-1ea3f00bebeb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9705b882-2b3f-483b-9d6a-5d72d26cfcd0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e98961b6-4138-418f-a847-a29bba3bc5c8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8217d056-aca5-4624-bf0a-804d580df97d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_62878cce-e2e8-4fd9-ae88-4f8bb6c33d86_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_94769cc5-9c27-42d1-bfeb-f94620a7f49b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9cd602c3-9861-4075-9d9f-6520fa0e7278_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3613a982-45e1-4c7f-9e70-b0e3bd04f03a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_318797c2-3333-46c6-a422-1a2d56fecf54_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lxrx-20201029_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:c8dd698f-3175-4c15-b175-8de9529d1e6f,g:e7b78c0d-300e-459f-a2da-2d0531ddecba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20201029.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_12077d40-2133-471d-8b8a-56f997764dfc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_DocumentType_12077d40-2133-471d-8b8a-56f997764dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_63108e67-f6ff-40a0-9ed8-77d69ee9bc4c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_DocumentPeriodEndDate_63108e67-f6ff-40a0-9ed8-77d69ee9bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a2a9843e-a13b-41a6-95bf-ed055a90aa67" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityRegistrantName_a2a9843e-a13b-41a6-95bf-ed055a90aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a1498d63-0d7a-4763-bb2c-dc7c5a32cabb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a1498d63-0d7a-4763-bb2c-dc7c5a32cabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1cca1495-8394-4918-8e96-9801faac6ce8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityFileNumber_1cca1495-8394-4918-8e96-9801faac6ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1de4ed71-11a1-4fe4-aed5-5318effab796" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityTaxIdentificationNumber_1de4ed71-11a1-4fe4-aed5-5318effab796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_dfd5ee57-f044-43d9-ae52-ab520b4f7383" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityAddressAddressLine1_dfd5ee57-f044-43d9-ae52-ab520b4f7383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_792a99b7-d33a-45b0-a20d-53b04ea7af8e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityAddressCityOrTown_792a99b7-d33a-45b0-a20d-53b04ea7af8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f298520e-344c-41ef-8312-22e4b8c9725f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityAddressStateOrProvince_f298520e-344c-41ef-8312-22e4b8c9725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cebc6200-901e-4e6b-8fd3-400fee1bbffb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityAddressPostalZipCode_cebc6200-901e-4e6b-8fd3-400fee1bbffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fba552fe-fba5-449e-9818-51f6e2fb0dd5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_CityAreaCode_fba552fe-fba5-449e-9818-51f6e2fb0dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_83f78de1-5acf-484b-bee5-b3560e4d7ebf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_LocalPhoneNumber_83f78de1-5acf-484b-bee5-b3560e4d7ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5f7a2911-cc70-4bdd-b61a-b48a0518f6ac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_Security12bTitle_5f7a2911-cc70-4bdd-b61a-b48a0518f6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cb68486e-221e-4eb7-ad0e-d7189c443215" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_TradingSymbol_cb68486e-221e-4eb7-ad0e-d7189c443215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f8379ba8-abcf-4c48-b206-fb013570bafd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_SecurityExchangeName_f8379ba8-abcf-4c48-b206-fb013570bafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_36e5e69b-accc-4957-b50b-a1c58cf3649c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_WrittenCommunications_36e5e69b-accc-4957-b50b-a1c58cf3649c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e45bf0b4-c432-49aa-b598-fcd7d7d91a34" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_SolicitingMaterial_e45bf0b4-c432-49aa-b598-fcd7d7d91a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b043dde4-08a6-4947-ac7b-cb9866ba162b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_PreCommencementTenderOffer_b043dde4-08a6-4947-ac7b-cb9866ba162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_077a3a8c-2b13-4a36-9733-4d74ef4c2196" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_077a3a8c-2b13-4a36-9733-4d74ef4c2196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6cf087f2-93b8-4d64-862c-05b9d41f8137" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityEmergingGrowthCompany_6cf087f2-93b8-4d64-862c-05b9d41f8137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_84b51523-b3c0-4562-b1b3-9b9c36fbc8e2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_EntityCentralIndexKey_84b51523-b3c0-4562-b1b3-9b9c36fbc8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_75f85ba9-6975-4eb1-aee2-8302d2e67b98" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6550a78-19f2-48ad-a21b-a49c201df107" xlink:to="loc_dei_AmendmentFlag_75f85ba9-6975-4eb1-aee2-8302d2e67b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>7
<FILENAME>pressreleaseearningsq3.htm
<DESCRIPTION>EX-99
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie452e801cdf34085ac294995ce70c46c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Conference Call and Webcast at 8&#58;00 am Eastern Time</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">The Woodlands, Texas, October 29, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> - Lexicon Pharmaceuticals, Inc. (Nasdaq&#58; LXRX), today reported financial results for the three months ended September 30, 2020 and provided an update of key milestones.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;In the third quarter, we streamlined our operations to prioritize our focus on our advancement of LX9211, a promising drug candidate with potential to become a treatment option for the millions of people living with neuropathic pain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Most people suffering with neuropathic pain experience only limited success with available therapies while enduring substantial side effects,&#8221; said Lonnel Coats, Lexicon&#8217;s president and chief executive officer. &#8220;We have commenced our first Phase 2 study in diabetic peripheral neuropathic pain and plan to commence our second Phase 2 study in post-herpetic neuralgia shortly with results for both studies expected by the end of next year.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Third Quarter Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LX9211</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commenced patient dosing in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Enrollment is expected to total approximately 300 patients at 30 U.S. clinical sites.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Preparing to commence an additional Phase 2 study of LX9211 in post-herpetic neuralgia later this year.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Realignment and Debt Reduction</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Realignment of the business around LX9211, sotagliflozin and other drug discovery and development programs.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Reduced outstanding debt by more than 90%, including the elimination of its $150 million secured term loan and $75.8 million principal amount of its 5.25% Convertible Senior Notes due 2021.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">XERMELO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (telotristat ethyl)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">XERMELO U.S. net sales were $6.5 million in the third quarter of 2020, reflecting sales during the quarter prior to the completion of the sale of XERMELO and related assets to TerSera Therapeutics LLC on September 8, 2020.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Received $160.4 million in cash at closing of the sale and eligible to receive up to $65 million in additional milestone payments for the development and commercialization of XERMELO in patients with biliary tract cancer and mid-teens royalties on net sales of XERMELO in biliary tract cancer.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Sotagliflozin</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes&#58; SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">all four studies meeting their primary objectives of lowering A1C in patients with type 2 diabetes.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Upcoming Milestones</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Q4 2020&#58; Initiation of a Phase 2 study for LX9211 in post-herpetic neuralgia.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Q4 2020&#58; Presentation of data from the sotagliflozin SOLOIST and SCORED Phase 3 studies at the American Heart Association Scientific Sessions 2020.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Q4 2021&#58; Phase 2 study results in diabetic peripheral neuropathic pain and in post-herpetic neuralgia.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Third Quarter 2020 Financial Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Revenues&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Revenues for the three months ended September 30, 2020 decreased to $6.6 million from $294.4 million for the corresponding period in 2019. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The three months ended September 30, 2019 included collaborative revenues of $260.0 million from the termination of the alliance with Sanofi and recognition of the remaining amount of $23.5 million allocated to performance obligations from the initial agreement with Sanofi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Net product revenues for the three months ended September 30, 2020 consisted of $6.5 million from net sales of XERMELO in the U.S. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cost of Sales&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Cost of sales related to sales of XERMELO for the three months ended September 30, 2020 and 2019 were $0.6 million. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Research and Development (R&#38;D) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Research and development expenses for the three months ended September 30, 2020 increased to $40.1 million from $26.7 million for the corresponding period in 2019, primarily due to increases in external clinical development costs related to sotagliflozin subsequent to the termination of the alliance with Sanofi.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Selling, General and Administrative (SG&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Selling, general and administrative expenses for the three months ended September 30, 2020 decreased to $12.0 million from $13.9 million for the corresponding period in 2019. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Gain on Sale of XERMELO&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">A gain of $132.8 million was recognized for the three months ended September 30, 2020 from the sale of XERMELO and related assets to TerSera.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Net Income&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Net income for the three months ended September 30, 2020 was $82.6 million, or $0.71 per diluted share, as compared to net income of $226.1 million, or $1.95 per diluted share, in the corresponding period in 2019. For the three months ended September 30, 2020 and 2019, net loss included non-cash, stock-based compensation expense of $1.9 million and $3.6 million, respectively.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cash and Investments&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> As of September 30, 2020, Lexicon had $111.4 million in cash and investments, as compared to $271.7 million as of December 31, 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Conference Call and Webcast Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Lexicon management will hold a live conference call and webcast today at 8&#58;00 am ET &#47; 7&#58;00 am CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is (888) 645-5785 (U.S.&#47;Canada) or (970) 300-1531 (international). The conference ID for all callers is 7787988. The live webcast and replay may be accessed by visiting Lexicon&#8217;s website at http&#58;&#47;&#47;www.lexpharma.com&#47;events.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">An archived version of the webcast will be available on the website for 14 days. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">About LX9211</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">LX9211 is a potent, orally delivered, selective small molecule inhibitor of AAK1, a target with a pain phenotype discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. Lexicon holds exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1 under the alliance.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">About Sotagliflozin</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Discovered using Lexicon&#8217;s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index &#8805; 27 kg&#47;m</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">About Lexicon Pharmaceuticals</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. Through its Genome5000&#8482; program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in diabetes and metabolism, neuropathic pain and other indications. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For additional information, please visit www.lexpharma.com.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Safe Harbor Statement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">This press release contains &#8220;forward-looking statements,&#8221; including statements relating to Lexicon&#8217;s financial position, long-term outlook on its business and the clinical development and therapeutic and commercial potential of its drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon&#8217;s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management&#8217;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#8217;s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#8217;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#8220;Risk Factors&#8221; in Lexicon&#8217;s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie452e801cdf34085ac294995ce70c46c_116"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Selected Financial Data</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,351&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,404&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,763&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,910&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,209&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="padding:0 1pt 0 12pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,634&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,448&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,796&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,346&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;asset amortization)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $1,029, $1,698, $5,154 and $5,369, respectively</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,659&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,318&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,997&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,798&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,271&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible asset</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,638&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,638&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="padding:0 1pt 0 12pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,777&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,772&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,956&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,684&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income&#58;</font></td><td colspan="3" style="padding:0 1pt 0 12pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO</font></td><td colspan="3" style="padding:0 1pt 0 12pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,818&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,818&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,675&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,676&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,342)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,662&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishments, net </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,118)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,204)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,374)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,485)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,080&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) before income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,603&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,072&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,257&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,014&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,014&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,603&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,086&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,271&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,309&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,272&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,200&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</font></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,552&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,640&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,742&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="3" style="padding:0 1pt 0 6pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept. 30, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec. 31, 2019</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash and investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Property and equipment, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,106&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,047&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,716&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,928&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,715&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Current and long-term debt</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,320&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,183&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Accumulated deficit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,394,523)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,341,444)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total stockholders' equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,639&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,101&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie452e801cdf34085ac294995ce70c46c_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">For Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Chas Schultz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Executive Director, Corporate Communications and Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Lexicon Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">(281) 863-3421</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">cschultz&#64;lexpharma.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>lxrx-20201029_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20201029.xsd" xlink:type="simple"/>
    <context id="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-10-29</startDate>
            <endDate>2020-10-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV80L2ZyYWc6MmIyOWUyZjZkYTJkNGI0M2FhYTNkNjU3YjQ4ZjViYmYvdGFibGU6Y2QyN2Q3MzIxY2RlNGNmOTllMjcwMDhjZTQ1ZjRiM2IvdGFibGVyYW5nZTpjZDI3ZDczMjFjZGU0Y2Y5OWUyNzAwOGNlNDVmNGIzYl8wLTEtMS0xLTA_2708a7ff-a57e-4151-b715-c6384dfd4077">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV80L2ZyYWc6MmIyOWUyZjZkYTJkNGI0M2FhYTNkNjU3YjQ4ZjViYmYvdGFibGU6Y2QyN2Q3MzIxY2RlNGNmOTllMjcwMDhjZTQ1ZjRiM2IvdGFibGVyYW5nZTpjZDI3ZDczMjFjZGU0Y2Y5OWUyNzAwOGNlNDVmNGIzYl8xLTEtMS0xLTA_d51d5f33-c02e-45ba-ae1d-f10680e77da8">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg3_282c8636-84b7-449f-88fb-0f1fd2278c6c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8yNjY_854c95c3-cffb-438c-aabf-d5478d978c9a">2020-10-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjgw_49e0a411-6141-492b-894c-b6b777c801f0">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6ZGNkMTlkMzg1ZjNmNDg2YzhiNDhmYWU0OGZhNjg5OTQvdGFibGVyYW5nZTpkY2QxOWQzODVmM2Y0ODZjOGI0OGZhZTQ4ZmE2ODk5NF8wLTAtMS0xLTA_a3102990-8f12-46a0-a825-135a2fffed25">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6ZGNkMTlkMzg1ZjNmNDg2YzhiNDhmYWU0OGZhNjg5OTQvdGFibGVyYW5nZTpkY2QxOWQzODVmM2Y0ODZjOGI0OGZhZTQ4ZmE2ODk5NF8wLTEtMS0xLTA_79e5b1d6-1991-41ba-b0f2-2536fca97427">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6ZGNkMTlkMzg1ZjNmNDg2YzhiNDhmYWU0OGZhNjg5OTQvdGFibGVyYW5nZTpkY2QxOWQzODVmM2Y0ODZjOGI0OGZhZTQ4ZmE2ODk5NF8wLTItMS0xLTA_4dbf7b62-0d7f-414d-a0d4-0e4537cab5a7">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg0_51064a4e-e70c-4ecd-8668-5f4a9fa0e867">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjgx_c4e3c6d6-2f3e-403d-9e05-e40c4674e89d">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjkx_5cded6e1-9911-4b2d-811a-2a57f1f6d6a1">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV80MDk_ab8271da-c4c8-426a-b5c4-9a334baf00f8">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV80Njg_45de67f8-5aba-42bb-9e97-eae849f02918">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg4_29e2cc8f-c70e-4aed-877f-fe50fa9a1b66">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6YTZmZDQ0YjE1Nzk3NGQxMzliOTM4NTEyMjNmNGZhYzEvdGFibGVyYW5nZTphNmZkNDRiMTU3OTc0ZDEzOWI5Mzg1MTIyM2Y0ZmFjMV8xLTAtMS0xLTA_6a4c2205-6953-4ed2-ad55-d18e3528e73c">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6YTZmZDQ0YjE1Nzk3NGQxMzliOTM4NTEyMjNmNGZhYzEvdGFibGVyYW5nZTphNmZkNDRiMTU3OTc0ZDEzOWI5Mzg1MTIyM2Y0ZmFjMV8xLTEtMS0xLTA_f5734488-c314-402e-bc94-cb8d3e0cc40e">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGFibGU6YTZmZDQ0YjE1Nzk3NGQxMzliOTM4NTEyMjNmNGZhYzEvdGFibGVyYW5nZTphNmZkNDRiMTU3OTc0ZDEzOWI5Mzg1MTIyM2Y0ZmFjMV8xLTItMS0xLTA_643af199-3290-4fa4-a368-529645a075a7">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjky_e2dd2f38-a87e-410c-a073-2833c565373f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjk0_542b535e-838d-4d53-8aff-045af3fec4df">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg5_6674df88-fa04-4c88-b95e-8b804697d99a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjg2_8e44b3e5-e891-4a17-bc37-e380216fc17a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkM2IxNmQyNDE3NTRjNTNiMzUyODQ3M2Q0ZWZmOGE5L3NlYzphZDNiMTZkMjQxNzU0YzUzYjM1Mjg0NzNkNGVmZjhhOV8xL2ZyYWc6NjliN2QwNjlmYzRkNDcwMWFkYzVlMGFkNDllNGEwODEvdGV4dHJlZ2lvbjo2OWI3ZDA2OWZjNGQ0NzAxYWRjNWUwYWQ0OWU0YTA4MV8xNjgz_157a371a-0297-43b2-b30c-49666c89d2db">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140662077440888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 29,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 2CA=4660>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
M8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#
ML9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/
MN]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DW
MY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !*
M.%U1!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( $HX75%PFK%![@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $HX75&97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ 2CA=4>Z?[ZTU!   /1   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $HX75&#J:4#U $
M #(&   -              "  7@,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  .\2      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20201029.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrx-20201029.htm">lxrx-20201029.htm</File>
    <File>lxrx-20201029.xsd</File>
    <File>lxrx-20201029_cal.xml</File>
    <File>lxrx-20201029_def.xml</File>
    <File>lxrx-20201029_lab.xml</File>
    <File>lxrx-20201029_pre.xml</File>
    <File>pressreleaseearningsq3.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20201029.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20201029_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20201029_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20201029.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20201029_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20201029_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20201029.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20201029",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20201029.htm",
      "contextRef": "i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.lexpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20201029.htm",
      "contextRef": "i85553cc795cb437b93a27ff28ff7079c_D20201029-20201029",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001062822-20-000063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-20-000063-xbrl.zip
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M<"0WVU(8OQ\(GGU6-K*)A44=4%-DJGJUJ%L+NRZR4-'TS0)%#Y^N3OF.P=)
MR<CIR^1O-F"! I\Y?I"WGO7'8#'*A[ .HX\+.OR;9%P?#(8',)JN[B26_)*V
M39$*G9N(F;ERT7V'>5WN<@.IEE(G)IGPRCRK2"6CP'2"[HJK>]S;_28C%PRK
MHNL?))[S:BUX6S IO8]%Q"X39=XB<KU69 ?39$PD/_A2:$""EK)T_"B%7^.?
MYE'^3 +?U47-ME8V5>,Y]J^BEG5C,?OW*<V:97#F7[]5HTR,Q2Z66M&ML0_M
M#LX'QX5;7-%0S?!6EBIMS=:G9E1^PGZU6_[&S\V@FDC<V!_>LGU72#X>1;?,
M?Y&6V@IM5UR,J.S$$MUX&5TR,#N7JN^MQIZW--*^)ZZ;[-V,!>6_6)&99H5;
M(5@<RJ#1/VJYEP('OV0^QU'A<X"U][V+)1'/[,C-"ELQ*J]=R]4;^^R&678W
MIO'"7T18Q?"1HKYQ_.C''0]=[-<-CF$$+!V!^+SZE<.W#5^%#A_=,OR&SL'-
M^\;S5, _(S\N?*#%G//UAW((? 0NK<M&,NZ?!0V*R MT TYV IR %U%^+:TC
MP/_VI-LK&\ITO"@@/7HQ"J%2UAX;I;TH!NIX^;['\@Z.F]*R;='G>"(Z+5OJ
MZWLB1EG3S->_B]8L:U1]34]DKDUNO-C.^<'8DD'B(U=,W[?$[ZPLRO?R*L_P
M8YY;=,[HM'<UNM<VC-_"W)<_&5!%Z%X@?XGV_UN0^>>T^I-15$DJZ,_8AX[;
M9;03CP;/\;-?5U>*M0Q6I:HR-^FZ"KQ]9WQ]@:/]J$&Y!-9F+5;]%+IS%V#V
M-U]>/?@FV<*L_Z?NX5@R.Z1SG_VB8Y8&V!.AB+-,\BA,1+"P-_E21^*I]7Y>
M[]5X)]ZKW(&'859BYJ;59#0 7V/ZH'OQNF*\V"UFV<\C2P=KEM59LF>[Q)3.
ML^_M46@9#*<EI'1T\OJ.E&F4[05_*^1GN97[I?F<A1S"U2'Y1V5HED'[VZ9G
MWHZBI>5F<I+>=6+FUOHG<GW=>/,!OG:VIOQ@NF9E:;^**OPD]-@_"1W/R$_=
M09;KLS>/91CPXSNZ5LQ[J#@1G\(?8&6P]?]02P,$%     @ 2CA=49484I>&
M @  >@D  !$   !L>')X+3(P,C Q,#(Y+GAS9-U674_;,!1][Z_P\CPW'Z70
M1+1( R%-ZC:)@>!M<NR;UB*Q,]NAX=_/SL=*2F%TVL,VJ5*=ZW/.];F^=G)Z
M5A<Y>@"EN11S+QP''@)!)>-B-?=NKB_QS#M;C$:G[S"^^W"U1!>25@4(@\X5
M$ ,,;;A9HUL&^AYE2A;H5JI[_D P7C2D<UD^*KY:&Q0%4; [JQ(Z8^PXGF5X
M$IY,\1$-ISAUHQF#>!K%+(3C[/TJ@9/T9$8#AB=! /AH&F>81(S@B 732<@8
MT+05K76BZ1H*@JPQH9-:S[VU,67B^YO-9KR9C*5:^5$0A/[=I^77!NIUV)R+
M^P&Z3E7>XR>^FTZ)AI_P6M4#> YUN2:J(&,J"]_Y#8,H]A Q1O&T,G I57$!
M&:ER,_<J\;TB.<\X,%OS'%Q5!X GTX:H%9C/I !=$@IOR;H8(>2JP8M2*H/$
M7FY7CC".8[]V_CS45F\I*3%-2[Q8C@:/W1"'D=V^<:V9Y[\I[5"("VV(H'!(
M;ON$>]Z?6,-V;P];0\\[? V-F 8Z7LD'GP&WHF&,@] J[%^$?HGD!GC+'N8G
M0DC3J+A(%RM++C+9!FS(F4AZ)U>0]4?GV7G8TR[-7T(453+_16_YI9(E*,-!
M/SU+C<!:03;WW(G"?0=_HR0?VY7TD&<)AMOAIGU+H57>V%UN_?0*YK&T"MIN
M20YMA?YF^PRR0^U;"A?\OW"?D_10]Y8"^3]OO%1PJ'%+T?;E\3MM[_C7=AYQ
M-O?.I?T0\)"+W5Q]?.4ETV1MT;U<+[AMP45@7[+VA_#VHP&CAG7J[V)W5"H-
M[(M8-.-==QVY@[Q"W+D,WLP;GJ*]M"[85Z^[6OWAW=H^/[E_FT![M2]&/P!0
M2P,$%     @ 2CA=47M*9-&  0  R (  !4   !L>')X+3(P,C Q,#(Y7V-A
M;"YX;6R=DE%OVR 0Q]_S*1A['0;;=6-;<2HMTZ1)V4O:JGW%<(Y1L+& UNZW
MGW&:3>TV3=H+<,?O[G]WL+F9.HV>P3IE^@K'$<,(>F&DZH\5OK_[2G)\LUVM
M-A\(>?Q\V*,O1CQUT'NTL\ ]2#0JWZ('">Z$&FLZ]&#L23US0K9+T,X,+U8=
M6X\2EK#WM[84N9371=Z0-%YGY$K$&:G#*9=09$DA8[AN/AU+6-?K7#!)4L:
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M]AZJBI/Z.">J/R!*HPGG&).DQS<!+]SPT*N :W9%_989+B9'1DV:O"=?ZOW
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M;A*3WN+G=5N-\8G=ZTAG+H+6V1._&]0X%M/.X1A](8A:A=H?AI'8R_[8!P.
MV[Y[,B!/DAZZF[**U3"%N]VN-LTF@AX#-+&739^NJDJKVHV]^>]JK:K5;CSX
MM5FU7OA=RW[9K(\!:SE5T[17 &RMM0)@[6J]5AC,EL BL+6'7SK]Y"Y)F98T
MD-AHR(-_OJN9[^XTE>[9PUMFS;:4:IT\EWPF!;&Z@^$?BKY)W3UZV/A8M6W>
MNB]HRQ]\I$D_YA&/^7TKOF,FZUJ13R-A#@<F8F"*F=YL:&I2LELFAH!7Y4N/
M90A=SU1;O];[96<1T<&NZS<2G"?OV2#!.50!X88BWXM)0@(<^K/) ?ESLO1"
M:K?OD@CW\!ZFSYIU3WLA#%Y2^?571>77Q_/EUPO@;2%D;!52O^%^QZMPN@&"
MNWA2FG"V0U=?J"32MZ&(6Q=01MT%U%5 QY9\6H84+X2P_/'4]%TP^;)#!4&?
MU2ZYI^2>M^>>!;7V,MS18MG2!7V\G1\!3SR\]F8IZK_$T0L<MF)Y'H_Z&?<>
M$/3FX6(Y]"5\]N"]CG<8D.'OQM.,"!*P)BZ\YS":Y_(B,UEC!LGW"*/)%A3)
M]6'BP]UUW[>,N=M)\P-_PZ@[]L?W5L.<TR;W:T?VG!6]0-9*-E@'_"VC5K=*
M-MAV-K!KAF,Z)1^4?& T&[7<\,'6^%6',Z<WCH] C%[M7(T?L.^->NX5J9SQ
M)-5TV?NY8<K-P*K=JAMMRRRQNE2LUO*C.S<#H7:K;=AF.S=8W1J+=#Z^WV=2
M8;RLB'\#^+*=J]AY Q!JM9HE1I=KB^KY49L;@M%F?D+DYVUM:.3:>38XETHW
M,^EMCA?8&%S>X_RV\,Y9$9BQ831JC[/C<S8*UR#]&T4-N^T8CM,JZ9$7>M2,
M9KM1DB,GY*A9-:/F%(0>RZT:6!_2S\;=VN*^X^;SL75>#GV!)Y?KS,'L!2<[
MDZ;V+E[Q(RJ^U(=QQ3R@&X]+?LS7T*U)<6EK]-!/NAH [[8":/61FDNIXRMN
M]-LHD]M+QFB]6>:\EIQ%--IVF?5:<BAE./7\\.G]_:2U1?M)']Z+R+M9WM"A
M6^-M/'0QG#%S(MD#%\'0!3"&:;<-_-UHM^!WW;#JCKX*IF[4&NW92V#*3;IW
M7QS3L)S\J*[-0*K=,!KESM*R_9:Z;31*SV79_K5EU*S'<_*;[+J4OD[IP"Q1
MFA:X*71A7Z;5K),GTVHXY,DXCCGV9)IFZ<G,V0<(;-NE)[-DI-:,5CL_YF$S
MD H^=[-$ZK*1:AMV,S]M6EMC\DX&0RY#.AV9[F[%VV82Z>,BRM:,LC6CQ&J!
ML&H9#;-L=]EL3MUFPS0IJ-"WVI?V*7_\N1E8M5M&HU:Z^"6KYA^K.6/59=JG
M(G1SJ+D*U+*OX\E-"]MH/E$7E)M*Z2T@1Z,-Y'B\V;,DQQM&<>V&T:X7I)%@
M&^AA.T:C59 ^M(UI[*!N_(EQE8&K!N)%S1V/V->\;[P6:>C6)"9^Q5OY\"YC
M[M.M=G\<GW\]/CU;B=M7.%U9LXU6CNI1-@.K9>!<\FI1L)HW7EV26<JO.3HA
MSXCM8)+\D[[5='RC[+-S$5ODUK<:1J-9+X97OP7DL#'*:I91;U[HL>.81LVQ
MYQI"2U*LX=RPEM%H%"1!]X2]S:ZL#50@'I^]'+GZD26Q"C3RC3S9M5X!<YI6
M>GBB$S. $^!.9-1/+X@/1,SR<$#!6E&T8]?K#UGEERGZ\7*V%J>K"UI+W);\
MNA7\N@W6Z01OEQ-1G)5ZE+;(,2RK54KWDK%:-VS3*;&Z9*Q:CE%KEFA=.EKK
MAM/*BX7?@FQ_:H(F5Q;HT@B*CO)@D-9X JN9G_[!S<!HV4ZT_!:M5GFOQM)/
M;S-;^>'3;0B$\(Y<.;/OW!%=%8KLPYC?/K\.?HMV=%JVT3 ?/VHT-QLZ6T .
MVS8-LZR SPT]=NHUH$>[W'M>/RFL9MVPGS@;-3?T*+<S"S2R)%:!1I;$*M#(
MDE@%&KD-X>+)."J$.#$07;GEB<J\U<AO!E8;AFGEY_+*S<!IR:F;SZG;8('F
M$I:O,$!+"?-SAZ$/KPWNG[&KNSTIU]?4!Y1\5D0^LVW0[JTW[V,J&6W;&.WM
MD^0ECVT;CUDMZ\E3N?/$:/=?/Y(>L_'",.-%0Z>04H-E>RK!0TOO8J5\9_[>
MN971$!N*$%8[&."Q-GT>"H-U>"3=UT=)FZ/3"Z2VS>I*;EU=@OTOV6$=(4G5
M6L6UQB4[%),==LQJW<Q)O7[)"NOU[ZLKN7(G[^T;N7>^/.DGL?!*]ZN04F7F
M3*I*=EBSDFT_?LQ8R0[;Q ZE^U6RPE@SK.26\26G3UMOGCTMARXIBUE2LO!#
M-^5 _PN,;"*6X%W9,L!X9YC0R?[!&R2C-Z!FS#*;1LU<A;G8YDH\RVP8]A.=
M?R567X+5=C,_%8Z;@U4[1P<RE);IY9FZ3;R)U+*:1KU>ZM)E8[5A-)S\2/V&
M8+6T4"OBU::3'PWPRBCX826]K ?*H255RZ'/\2;S!?2:2DJ?K+.=UJ>NP",#
MUY3W;MYK)PXBIKH+N,P++;E$W9HBMK7BX5 %1$8.P1?[%_=YX IVT1<0LAWQ
MF"\C5UCLH<5@YPLQC*NL9AK,-FUS-50K CL?"1?08"$:K/9VB#?-N"=C>)N[
MR+;Y2<#BODI@5N]5[;L%'[I!MFSG1\ 33X(&7S(]E^4W;&V-HH[@IW\>\JA/
M9T[+X%I$,5W(LR5"N&@R)G=4W(0*&<LR'.?Q;NIBU4RM+SNW''98XRFM3<MH
MK*1@JCPW97%#\#W$VX7C$1D#\3.10[0%2[M]H$A#"WUO!RA6R\R;8MV$/1#'
M,)U5=%^62FIQ)?6K4MZ-]/U2(Q5((SF.47?RUJA:HK;L]%N>7CI++VR*>="3
M>&H%CR*Q-8'T9LA2#N_>W!C<6FVC:>7**=U./76I8NZ7RJF  M1L&6V[E2<)
MVHRPSK&:H)I6T<=;QG7/V(5(PE $^O)+7P6]2BS" ?-$I\P]%4E+V:91LU=1
MTIP+);5>U#IUPVJ5H=[:5=6!ZR:#Q*?Z)$]TI;N<2R^*-+30@K1C&;6V8]3M
M6G[.:M@<S#JXK9N7N]BW4T'I&"^*E7O55[XGPN@?M)\7CTH]52!I:C6-1BU7
MIXAL#&JQH=%:R9WRKU-5NS'O^ )^>_+ZRV?ZH6'KX)<IF-EWV73IRAR[VJS#
MZH<JDK%4 )\ 'T5>B_T;Z<7]=.73#VI8]\S)([P3*>QZG7OD03BF?^+4TOOG
M.RF<NBU:IN5ZW9ICMNK<M=M.NUUW1=-TG8;[W^:[[)E^.,%*3U0ZH>!7%=Z%
MZ&^/^S=\%,V"/)!!Y<YZGPGJU&13M/PSB6+9'2V=':VGRB4=!\#^187L)  -
M'<K)Y=JK!61.+@B0C^_KK?T'&>U!?#W.GVM \_VK.^SSB%VX_<2/_\H_M,>W
MPDU0?MF1#(4;J]!@ARH<JA B#_AK,$@"4#PHMQ&E34ZH?A-8Z9P$'S[._R)/
MQ:UT5<"^]WDXX*Y(2)<6 / =NV5]8JU&K5)S;"O_\+J1YON/[QO.OB]NAX3P
MJJL&<[ 7RN;L=I0W@E_]>.!_^7]02P$"% ,4    " !*.%U15I1RA?43  #>
MAP  $0              @ $     ;'AR>"TR,#(P,3 R.2YH=&U02P$"% ,4
M    " !*.%U1E1A2EX8"  !Z"0  $0              @ $D%   ;'AR>"TR
M,#(P,3 R.2YX<V102P$"% ,4    " !*.%U1>TIDT8 !  #( @  %0
M        @ '9%@  ;'AR>"TR,#(P,3 R.5]C86PN>&UL4$L! A0#%     @
M2CA=41I)Q=P% @  ;08  !4              ( !C!@  &QX<G@M,C R,#$P
M,CE?9&5F+GAM;%!+ 0(4 Q0    ( $HX75&W[XSM5PH  *)=   5
M      "  <0:  !L>')X+3(P,C Q,#(Y7VQA8BYX;6Q02P$"% ,4    " !*
M.%U1N\\,$ZD&  !H,0  %0              @ %.)0  ;'AR>"TR,#(P,3 R
M.5]P<F4N>&UL4$L! A0#%     @ 2CA=4;F-+U*&'0  S&P! !H
M     ( !*BP  '!R97-S<F5L96%S965A<FYI;F=S<3,N:'1M4$L%!@     '
-  < T@$  .A)      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
